Outcome of Board meeting held on 12th February 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kerala Ayurveda's Board approved its Q3 FY26 (Dec 2025) standalone and consolidated results. Standalone revenue for the quarter rose to Rs. 23.04 cr from Rs. 19.48 cr YoY, but the company reported a widened loss after tax of Rs. 3.47 cr vs Rs. 0.08 cr, with 9M FY26 loss at Rs. 6.81 cr (vs Rs. 1.92 cr). On a consolidated basis, 9M FY26 revenue grew to Rs. 108.71 cr but loss attributable to owners widened to Rs. 11.49 cr. The Board also approved converting a Rs. 20.66 cr unsecured promoter-group loan from Katra Holding into 6,30,000 equity shares at Rs. 327.99 each, and acquiring the remaining 26% stake in subsidiary Ayurvedagram Heritage Wellness Centre via a share swap of 304,887 shares (~Rs. 10 cr), making it a wholly owned subsidiary. An EGM is set for March 14, 2026, and 12,868 ESOP options were granted at Rs. 10 each.
Mixed for shareholders — revenue continues to grow but losses are deepening, which is a negative signal. However, the promoter loan being converted to equity reduces debt, and the full consolidation of Ayurvedagram simplifies the group structure, both of which are mildly positive. Shareholders should watch the March 14 EGM for approvals and monitor whether the wider losses narrow in coming quarters.